Financial - Conglomerates
Compare Stocks
2 / 10Stock Comparison
BSLKW vs PRAX
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
BSLKW vs PRAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Financial - Conglomerates | Biotechnology |
| Market Cap | $4K | $9.63B |
| Revenue (TTM) | $1M | $-92K |
| Net Income (TTM) | $-24M | $-327M |
| Gross Margin | -6.8% | — |
| Operating Margin | -30.3% | — |
| Total Debt | $13M | $110K |
| Cash & Equiv. | $4M | $357M |
BSLKW vs PRAX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 24 | May 26 | Return |
|---|---|---|---|
| Bolt Projects Holdi… (BSLKW) | 100 | 2.7 | -97.3% |
| Praxis Precision Me… (PRAX) | 100 | 552.5 | +452.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BSLKW vs PRAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BSLKW is the clearest fit if your priority is growth exposure.
- Rev growth -60.1%, EPS growth -13.3%
- -60.1% NII/revenue growth vs PRAX's -100.0%
PRAX carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- -20.1% 10Y total return vs BSLKW's -97.4%
- Lower volatility, beta 1.55, Low D/E 0.0%, current ratio 10.22x
- Beta 1.55, current ratio 10.22x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -60.1% NII/revenue growth vs PRAX's -100.0% | |
| Quality / Margins | 2.4% margin vs BSLKW's -47.6% | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +7.7% vs BSLKW's -76.0% | |
| Efficiency (ROA) | -40.2% ROA vs BSLKW's -218.1% |
BSLKW vs PRAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
BSLKW vs PRAX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
PRAX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
BSLKW and PRAX operate at a comparable scale, with $1M and -$92,000 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1M | -$92,000 |
| EBITDAEarnings before interest/tax | -$20M | -$357M |
| Net IncomeAfter-tax profit | -$24M | -$327M |
| Free Cash FlowCash after capex | -$5M | -$283M |
| Gross MarginGross profit ÷ Revenue | -6.8% | — |
| Operating MarginEBIT ÷ Revenue | -30.3% | — |
| Net MarginNet income ÷ Revenue | -47.6% | — |
| FCF MarginFCF ÷ Revenue | -11.8% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -142.1% | +2.7% |
Valuation Metrics
PRAX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $3,789 | $9.6B |
| Enterprise ValueMkt cap + debt − cash | $10M | $9.3B |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -24.72x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.00x | — |
| Price / BookPrice ÷ Book value/share | — | 8.54x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
PRAX leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), BSLKW scores 5/9 vs PRAX's 3/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | -43.0% |
| ROA (TTM)Return on assets | -2.2% | -40.2% |
| ROICReturn on invested capital | — | -65.0% |
| ROCEReturn on capital employed | -35.0% | -49.3% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 |
| Debt / EquityFinancial leverage | — | 0.00x |
| Net DebtTotal debt minus cash | $10M | -$357M |
| Cash & Equiv.Liquid assets | $4M | $357M |
| Total DebtShort + long-term debt | $13M | $110,000 |
| Interest CoverageEBIT ÷ Interest expense | -14.88x | — |
Total Returns (Dividends Reinvested)
PRAX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRAX five years ago would be worth $7,918 today (with dividends reinvested), compared to $263 for BSLKW. Over the past 12 months, PRAX leads with a +775.0% total return vs BSLKW's -76.0%. The 3-year compound annual growth rate (CAGR) favors PRAX at 174.9% vs BSLKW's -70.3% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -70.9% | +16.4% |
| 1-Year ReturnPast 12 months | -76.0% | +775.0% |
| 3-Year ReturnCumulative with dividends | -97.4% | +1976.5% |
| 5-Year ReturnCumulative with dividends | -97.4% | -20.8% |
| 10-Year ReturnCumulative with dividends | -97.4% | -20.1% |
| CAGR (3Y)Annualised 3-year return | -70.3% | +174.9% |
Risk & Volatility
Evenly matched — BSLKW and PRAX each lead in 1 of 2 comparable metrics.
Risk & Volatility
BSLKW is the less volatile stock with a -0.11 beta — it tends to amplify market swings less than PRAX's 1.55 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRAX currently trades 93.6% from its 52-week high vs BSLKW's 3.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.11x | 1.55x |
| 52-Week HighHighest price in past year | $0.15 | $356.00 |
| 52-Week LowLowest price in past year | $0.00 | $35.18 |
| % of 52W HighCurrent price vs 52-week peak | +3.2% | +93.6% |
| RSI (14)Momentum oscillator 0–100 | 45.7 | 55.6 |
| Avg Volume (50D)Average daily shares traded | 24K | 378K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $544.40 |
| # AnalystsCovering analysts | — | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
PRAX leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
BSLKW vs PRAX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BSLKW or PRAX a better buy right now?
For growth investors, Bolt Projects Holdings, Inc.
(BSLKW) is the stronger pick with -60. 1% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Analysts rate Praxis Precision Medicines, Inc. (PRAX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BSLKW or PRAX?
Over the past 5 years, Praxis Precision Medicines, Inc.
(PRAX) delivered a total return of -20. 8%, compared to -97. 4% for Bolt Projects Holdings, Inc. (BSLKW). Over 10 years, the gap is even starker: PRAX returned -20. 1% versus BSLKW's -97. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BSLKW or PRAX?
By beta (market sensitivity over 5 years), Bolt Projects Holdings, Inc.
(BSLKW) is the lower-risk stock at -0. 11β versus Praxis Precision Medicines, Inc. 's 1. 55β — meaning PRAX is approximately -1546% more volatile than BSLKW relative to the S&P 500.
04Which is growing faster — BSLKW or PRAX?
By revenue growth (latest reported year), Bolt Projects Holdings, Inc.
(BSLKW) is pulling ahead at -60. 1% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Bolt Projects Holdings, Inc. grew EPS -13. 3% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BSLKW or PRAX?
Praxis Precision Medicines, Inc.
(PRAX) is the more profitable company, earning 0. 0% net margin versus -47. 6% for Bolt Projects Holdings, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRAX leads at 0. 0% versus -30. 3% for BSLKW. At the gross margin level — before operating expenses — PRAX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BSLKW or PRAX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BSLKW or PRAX better for a retirement portfolio?
For long-horizon retirement investors, Bolt Projects Holdings, Inc.
(BSLKW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 11)). Praxis Precision Medicines, Inc. (PRAX) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BSLKW: -97. 4%, PRAX: -20. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BSLKW and PRAX?
These companies operate in different sectors (BSLKW (Financial Services) and PRAX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.